A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients

摘要

PurposeGeneric substitution of brand-name medications can lead to significant cost savings and is an accepted medical practice. This study evaluated clinical and safety outcomes among liver transplant recipients whose mycophenolate mofetil (MMF) was converted from the brand-name formulation (Cellcept) to a generic formulation (My-rept).